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Background: Redox stress is a hallmark of the rewired metabolic phenotype of cancer. The underlying dysregulation
of reactive oxygen species (ROS) is interconnected with abnormal mitochondrial biogenesis and function. In chronic
lymphocytic leukemia (CLL), elevated ROS are implicated in clonal outgrowth and drug resistance. The pro-survival
oncogene T-cell leukemia 1 (TCL1) is causally linked to the high threshold towards classical apoptosis in CLL.
We investigated how aberrant redox characteristics and bioenergetics of CLL are impacted by TCL1 and if this is
therapeutically exploitable.
Methods: Bio-organometallic chemistry provided compounds containing a cytosine nucleobase, a metal core
(ferrocene, ruthenocene, Fe(CO)3), and a 5’-CH2O-TDS substituent. Four of these metal-containing nucleoside
analogues (MCNA) were tested for their efficacy and mode of action in CLL patient samples, gene-targeted cell
lines, and murine TCL1-transgenic splenocytes.
Results: The MCNA showed a marked and selective cytotoxicity towards CLL cells. MCNA activity was equally
observed in high-risk disease groups, including those of del11q/del17p cytogenetics and of clinical fludarabine
resistance. They overcame protective stromal cell interactions. MCNA-evoked PARP-mediated cell death was
non-autophagic and non-necrotic as well as caspase- and P53-independent. This unconventional apoptosis involved
early increases of ROS, which proved indispensible based on mitigation of MCNA-triggered death by various
scavengers. MCNA exposure reduced mitochondrial respiration (oxygen consumption rate; OCR) and induced
a rapid membrane depolarization (ΔΨM). These characteristics distinguished the MCNA from the alkylator
bendamustine and from fludarabine. Higher cellular ROS and increased MCNA sensitivity were linked to TCL1
expression. The presence of TCL1 promoted a mitochondrial release of in part caspase-independent apoptotic
factors (AIF, Smac, Cytochrome-c) in response to MCNA. Although basal mitochondrial respiration (OCR) and
maximal respiratory capacity were not affected by TCL1 overexpression, it mediated a reduced aerobic glycolysis
(lactate production) and a higher fraction of oxygen consumption coupled to ATP-synthesis.
(Continued on next page)* Correspondence: marco.herling@uk-koeln.de
1Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of
Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, and
Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases
(CECAD), University of Cologne, Cologne, Germany
Full list of author information is available at the end of the article
© 2015 Prinz et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Prinz et al. Molecular Cancer  (2015) 14:114 Page 2 of 18(Continued from previous page)
Conclusions: Redox-active substances such as organometallic nucleosides can confer specific cytotoxicity to
ROS-stressed cancer cells. Their P53- and caspase-independent induction of non-classical apoptosis implicates that
redox-based strategies can overcome resistance to conventional apoptotic triggers. The high TCL1-oncogenic
burden of aggressive CLL cells instructs their particular dependence on mitochondrial energetic flux and renders
them more susceptible towards agents interfering in mitochondrial homeostasis.
Keywords: CLL, ROS, Organometallic nucleosides, TCL1, Mitochondrial respirationIntroduction
The current therapeutic challenges in cancer, including
chronic lymphocytic leukemia (CLL) the most prevalent
leukemia of adults in the western world, involve the tar-
geting of tumor-specific pathways in a more profound
fashion than accomplished by conventional cytostatics [1].
In CLL, chemo-immunotherapies with nucleosides like
fludarabine in combination with antibodies, have signifi-
cantly improved response rates [2], but the majority of
patients eventually relapse due to incomplete clonal
eradication and finally develop refractory disease. A
major underlying reason for such treatment failures are
resistances of the leukemic (sub)clones towards drug-
induced triggering of classical apoptosis [3]. Mediators
of such protection in CLL are a marked pro-survival im-
pact by micro-environmental niches [4] and genetic de-
ficiencies to evoke an adequate p53 mediated apoptotic
response. The latter is particularly found in the clinic-
ally high-risk subsets of 11q23/ATM or 17p/TP53 de-
leted/mutated CLL [5, 6].
A key to overcome such high thresholds for classical
apoptosis would be to exploit independent forms of (pro-
grammed) cell death. Such therapeutic strategies would
bypass major modes of resistance to most currently used
substances. We previously identified organochalcogens
(organoselenium, -tellurium compounds) to act as ‘sensor/
effector’ catalysts of reactive oxygen species (ROS), par-
ticularly in a specific tumor-to-normal cell fashion across
various cancer cell types, including CLL [7, 8]. These sub-
stances exploited the aberrant redox equilibrium of en-
hanced radical production and reduced glutathione (GSH)
buffer levels in CLL cells as their selective vulnerability
by increasing the elevated ROS levels towards a cyto-
toxic threshold. The therapeutic potential of modulating
ROS in CLL had been demonstrated by others as well
[9, 10] and this can be particularly efficient when mito-
chondrial respiration is simultaneously inhibited [11].
Encouragingly, ROS-mediated induction of CLL cell apop-
tosis was shown to be independent of p53-functional
status [12].
Elevated levels of ROS, the byproduct of normal cell
respiration, are a hallmark of the rewired metabolic can-
cer phenotype [13]. Due to their genotoxic effects and
messenger function in milieu-derived growth signaling,especially via the B-cell receptor (BCR) [14, 15], ROS are
implicated in transformation, clonal sustenance, and drug
resistance in CLL particularly in advanced disease and
after previous therapy [16]. Protective stromal cells pro-
vide cystine for anti-oxidant GSH synthesis to CLL cells
and thereby relieve their ROS stress [17].
A central oncogenic mechanism in CLL is overexpres-
sion of the adapter molecule T-cell leukemia 1 (TCL1).
Mice transgenic (tg) for human TCL1 driven by the Eμ
immunoglobulin (IG) gene enhancer (Eμ-TCL1) model
human CLL with most fidelity to its aggressive IGHV gene
unmutated subset [18]. Through a physical interaction
with the AKT growth kinase, TCL1 enhances proximal
milieu-derived signaling, particularly acting as a sensitizer
for BCR-triggered cellular fates [19]. High-level TCL1 is
associated with high-risk disease features and poorer
therapeutic outcome [19, 20].
These data provide strong rationales to therapeutically
exploit ROS as mediators of non-classical cell death path-
ways in CLL in the context of their notorious resistance to
apoptosis, especially linked to high TCL1 expression. We
therefore designed novel metal-containing nucleoside
analogues (MCNA) and present here their efficient and
selective cell death induction in CLL. This action was
indiscriminate of cytogenetic risk subsets and irrespective
of protective stromal cell contact. Their non-autophagic
and non-necrotic cytotoxic activity involved an early ROS
induction and was independent of p53 or caspase activa-
tion. We link the oncogenic impact of TCL1 to elevated
ROS and altered mitochondrial energetic flux, which re-
sults in an enhanced sensitivity to redox active agents, e.g.
MCNA, representing a potent vulnerability.
Results
Chemistry and selection of the novel organometallic
nucleoside analogues
We have been extensively studying butadiene Fe(CO)3-
complexes like Me-N69 and could show that their iron-
fragment is crucial for the cell death inducing activity in
BJAB lymphoma cells [21]. We found cytosine to be the
nucleobase most effective for cell death induction as well
as a non-polar protecting group at O5’ to be essential for
this substance efficacy [21]. There was no significant dif-
ference in activity between furanoid compounds (partially
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geners [21]. Given these observations, we designed opti-
mized MCNA. They were synthesized according to our
established protocols [21–23]. Based on chemical prop-
erties and extrapolated activity indices, 4 compounds
were further selected for this study (Fig. 1). Huni132 is a
ferrocene-based nucleoside analogue, which contains
Fe(II). Huni218 is the corresponding ruthenium congener.
Me-N69 is a butadiene Fe(CO)3-complex, which contains
Fe(O) and can donate up to three electrons upon oxida-
tion. Huni132, Me-N69, and Huni218 resemble natural
nucleosides with respect to the relative position of the
cytosine unit and the 5’-side chain. Dia-Me-N69 is formed
as a diastereomeric byproduct during the synthesis of
Me-N69. It features a stereochemically inverse, hence
‘atypical’, configuration at C1 and was added as a control.
The novel organometallic nucleoside analogues induce
marked in-vitro CLL cell death irrespective of the
presence of high-risk disease determinants or stromal
cell protection
Flow cytometry with AnnexinV (early-apoptotic surface
expression of the neoepitope phosphatidyl-serine) com-
bined with 7AAD or Hoechst stain (uptake upon late-
apoptotic or necrosis-associated membrane disintegration)
assayed the ability of our MCNA to trigger death of231inuH
Me-N69
Fig. 1 Chemical structure of the selected novel metal-containing nucleosid
and synthesized, with the 4 illustrated compounds selected for this study. H
corresponding ruthenium congener. Me-N69 is a butadiene Fe(CO)3-compl
the synthesis of Me-N69primary tumor cells from CLL patients and of healthy-
donor derived PBMC. Initial estimations of effective
compound dosages were performed by LD50 titrations
(Additional file 1 Fig. S1). Next, already after 24 h all 4
tested MCNA, with the highest efficacy noted for Huni132,
induced pronounced cell death in 25 CLL samples whereas
normal PBMC were significantly less sensitive towards
MCNA treatment (Fig. 2a). Solvent (Dmso) induced cell
death was negligible (mean/SEM: PBMC 3.7 %/0.9 and
CLL 5.4 %/1.3). This overall selectivity by the MCNA
was greater than observed for bendamustine at this time
point and for fludarabine, compared to which the
MCNA also proved to be more B-cell specific (Fig. 2a,
Additional file 1 Fig. S2).
To evaluate the activity of the MCNA across different
risk subsets of CLL (Additional file 1 Tables S1, S2), we
compared post-exposure cell survival of cytogenetically
high-risk cases [5, 6, 24] carrying 11q or 17p deletions
(N = 9,) with 12 good-prognosis CLL (normal karyotype or
isolated 13q14 deletion). The MCNA triggered cell death
was at comparable rates, independent of cytogenetic
disease subset (Fig. 2b). Responses were also mostly
irrespective of IGHV mutational status or of previous
therapy (Additional file 1 Fig. S3). Furthermore, the MCNA-
induced biochemical response of PARP cleavage, a distal
event in several routes of programmed cell death, was812inuH
DIA-Me-N69
e analogues. A panel of metal-containing nucleosides was designed
uni132 is a ferrocene based nucleoside analogue, Huni218 is the
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Fig. 2 (See legend on next page.)
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Fig. 2 The novel organometallic nucleoside analogues (MCNA) induce marked in-vitro cell death across all cytogenetic and clinical risk subsets of
CLL and can overcome stromal cell protection. Incubation (24 h) of primary CLL suspension cultures (n = 25) or healthy-donor derived PBMC (n = 9)
with MCNA (10 μM) or bendamustine. Cytotoxicity as per AnnexinV/7AAD flow cytometry ((apoptotic) cell death); means/SEM. (a) Significantly
(*** P<0.0001; ** P = 0.0012) higher CLL cell death induction by the MCNA (highest efficacy for Huni132) than in PBMC; a less pronounced
selectivity for bendamustine. Solvent associated cell death corresponded to spontaneous death rates. (b) CLL with low-risk karyotypes (normal or
isolated del13q14; n = 12) vs 9 CLL carrying the high-risk aberrations del11q or del17p (including 4 clinically fludarabine refractory patients) show
no significant differences in MCNA sensitivity. (c) Immunoblot-based detection of PARP cleavage induced by MCNA in 2 CLL representing the
clinical/cytogenetic profile of investigated samples (β-actin corrected densitometric values). (d) Increased in vitro cell death upon combination of
MCNA (5 μM) with 25 μM bendamustine (data from 5 CLL) including a synergism for Huni132 and bendamustine (dashed lines; * P = 0.006). Bottom:
corresponding levels of cleaved PARP (immunoblot, β-actin corrected densitometric values) of 2 exemplary CLL. (e) CLL B-cells from clinically
fludarabine refractory patients (n = 9, including the 4 from (b); cases #32-40 in Table S2) were cultured (48 h) in the presence of fludarabine (5 μM),
bendamustine (25 μM), or the 2 most efficient MCNA (10 μM). Cell viability after bendamustine (*** P = 0.0003) and especially MCNA (**** P<0.0001)
was significantly reduced while lost in vitro fludarabine sensitivity paralleled the clinical resistance. (f) MCNA, especially Huni132 (10 μM), more than
bendamustine (25 μM), overcome the strong pro-survival support mediated to CLL cells by cocultures with NKtert BMSC. Immunoblots depict PARP
cleavage in 2 representative cases (N = 5 total). Densitometric values (β-actin corrected) for cPARP/PARP are relative to those for Dmso (set as "1") for
each of the two culture conditions. BMSC coculture reduces spontaneous (Dmso) PARP cleavage (densitometry: case 1 *5.4 (suspension culture) vs
0.4 (coculture), case 2 **0.67 vs 0.07). AnnexinV/7AAD-based cell survival (not shown) paralleling these data (suspension vs coculture) was: 70.3 % vs
83.3 % (case 1) and 71.4 % vs 84 % (case 2). Increasing TCL1 levels (β-actin corrected densitometric values; only Dmso in suspension culture set as
“1”) also indicate an efficient protective feeder cell interaction [26]
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patients with distinct disease stages (Fig. 2c).
Next, we evaluated potential cooperative effects of our
novel substances with bendamustine, a well-established
clinically active drug with a good therapeutic index (low
toxicity) in CLL. We preferred this well-described alkylator
for this and some subsequent sets of experiments over the
conventional adenosine nucleoside fludarabine based on
bendamustine’s faster reaction kinetics (Additional file 1
Fig. S1). The fludarabine metabolism with synthesis of
cellular F-ara-ATP peaking after ≈ 48–72 h allows reli-
able efficacy recordings for fludarabine starting only at
48 h. Therefore, and since we already expected the
MCNA not to act as “classical” nucleosides [23], benda-
mustine appeared as the better comparison when the
24 h MCNA effects were studied.
Freshly isolated primary leukemic cells from 5 CLL pa-
tients were treated for 24 h with 5 μM of each MCNA,
alone or in combination with 25 μM bendamustine
followed by AnnexinV/7AAD flow cytometry and im-
munoblot (PARP cleavage) analysis. There were at least
additive effects across all combinations, with the most
significant cooperation observed for bendamustine with
Huni132 (P = 0.006) showing even a synergistic relation-
ship (Huni132: 79.8 ± 9, Bendamustine 70.8 ± 9, Benda-
mustine + Huni132 46.4 ± 7.5; all Mean ± SEM; Fig. 2d).
These effects were further corroborated by an increased
cleavage of PARP seen for those drug combinations
(Fig. 2d, bottom).
Fludarabine resistance in CLL remains a clinical prob-
lem. We therefore analyzed samples from 9 CLL patients
with clinically fludarabine-refractory disease for responses
to the MCNA; as 4 cases to all 4 MCNA (see cytogenetichigh-risk subsets, above and Fig. 2b) or as all 9 cases to
only Huni132 and Me-N69 (Fig. 2e). Importantly, the
MCNA and in part also bendamustine were still efficient
in the context of clinical and in vitro fludarabine resist-
ance (Fig. 2e).
The high apoptotic threshold of CLL B-lymphocytes is
significantly determined by milieu-derived signals. The
direct contact between leukemic cells and stromal com-
ponents, i.e. BMSC, was shown to protect from spontan-
eous and drug-induced apoptosis [25, 26]. We therefore
explored the influence of the MCNA on CLL cell viabil-
ity in a stromal cell coculture system as this represents a
higher fidelity model of niche-mediated resistance than
suspension cultures. For this, CLL cells were kept either
in suspension or as cocultures with the human BMSC
line NK-tert. After 24 h of drug exposure, cell death rates
and levels of cleaved PARP were recorded. In line with our
previous findings [26], we observed upregulation of pro-
tein levels of the pro-survival oncogene TCL1 in CLL cells
upon NK-tert co-culture (Fig. 2f). The BMSC coculture
protected CLL cells from spontaneous and in part from
bendamustine-induced cPARP-induction/cell death. In
contrast, the MCNA consistently evoked marked cell
death also in the presence of BMSC-mediated pro-
survival stimuli; in the case of Huni132 nearly to the same
extent as in the suspension cultures. For cPARP densitom-
etry see Fig. 2f; corresponding AnnexinV/7AAD double-
negative fractions of surviving cells (not shown) were
(suspension vs coculture; percentage-means ± SEM): Huni132:
23.3 ± 3.2 vs 34.6 ± 10.2, Huni218: 56.8 ± 8.2 vs 70.9 ± 7.6, Me-
N69: 38.8 ± 7 vs 62± 7.2, Dia-Me-N69: 66.5 ± 8.2 vs 86 ± 4.9,
and bendamustine: 89.3 ± 4.5 vs 94.5 ± 0.9. As the feeder
cells themselves remained unaffected by the treatment
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induction of leukemia cell apoptosis was not due to loss
of BMSC protection, rather CLL-cell specific. Furthermore,
only incubation of CLL cells in supra-physiological 100 %
(instead of 10 %) serum of either fetal calf or human origin
confered some degree of protection from Huni132 medi-
ated cell death (Additional file 1 Fig.S5).
Taken together, we demonstrated thus far that our novel
MCNA efficiently and specifically trigger cell death in CLL,
irrespective of the disease risk group or the presence of
protective cell-cell mediated micro-environmental signals.
The cell death induced by organometallic nucleosides in
CLL is non-necroptotic and non-autophagic as well as
independent of caspase-3 and p53
Currently, at least 3 mayor pathways of programmed cell
death are distinguished by characteristic cell fates, namely
apoptosis, autophagy, and necroptosis [27–29]. Upon
MCNA exposure, we identified morphologic changes that
were rather characteristic for apoptosis, namely pyknotic
nuclei and cytoplasmic condensations (not shown). They
paralleled the pronounced AnnexinV induction (above).
However, to discriminate in more detail among the
pathways involved in the MCNA-mediated CLL cell
death, we employed Z-VAD and necrostatin-1 as specific
inhibitors of caspase-mediated apoptosis and caspase-
independent necroptosis, respectively. In addition, we
tracked the autophagy-specific proteolytic conversion of
the marker protein LC3B-I to autophagosome associated
LC3B-II. We also analyzed the cleavage of PARP, which is
mainly, but not exclusively [30], triggered by the activation
of the caspase signaling cascade.
We found that the MCNA lead to PARP cleavage in
CLL cells without preceding caspase-3 activation (Fig. 3a).
Neither Z-VAD nor necrostatin-1, were able to prevent
the cleavage of PARP by the MCNA (Fig. 3a,b, Additional
file 1 Fig. S6). However, the PARP-inhibitor olaparib miti-
gated MCNA-mediated CLL cell death (Additional file 1
Fig. S7). This suggested that the MCNA-mediated cell
death is to a large degree PARP dependent, but not pro-
moted through classical apoptosis or necroptosis. Al-
though the presence of Z-VAD could not fully prevent
the generation of cleaved PARP by bendamustine expos-
ure, this pan-caspase inhibitor suppressed the otherwise
robust induction of caspase-3 cleavage products by benda-
mustine. Furthermore, while bendamustine triggered strong
P53 Ser15-phosphorylation, none of the MCNA evoked
such p53 phospho-(p)-activation (Fig. 3c). PARP cleavage
and higher cellular death rates by MCNA treatment were
not associated with autophagic LC3B conversion (Fig. 3c),
which however was the case for the positive control of
rapamycin (Additional file 1 Fig. S8).
Together these data suggest that the programmed cell
death mediated by the MCNA can be considered as a PARPmediated, caspase-3 independent, hence non-classical, way
of apoptosis that does not involve P53. This distin-
guishes these substances strikingly from conventional
agents like bendamustine, which acts at least to a rele-
vant part caspase-3 dependent and via P53.The induction of CLL cell apoptosis by metal-containing
nucleosides involves a selective ROS dependence
Caspase-independent cell death is important for organis-
mal protection upon failure of the caspase-mediated path-
ways, and can be triggered in response to cytotoxic agents
[12, 23, 31]. Damage of organelles including mitochondria
and increases of cellular ROS levels are frequently in-
volved in such caspase-independent cell death [12]. Based
on their chemical properties (ionic metals) we predicted
our MCNA to induce ROS in a Fenton’s reaction (iron-
catalyzed hydrogen peroxide synthesis). Therefore, we
analyzed cellular levels of ROS in MCNA-treated CLL
(n = 3) cells in relation to induced apoptosis to test for
this possible caspase-independent mode of MCNA ac-
tion. Recordings of cellular retention of the fluorescent
(oxidized) CM-H2DCFDA dye measured ROS levels at
different time points after drug exposure (2 h, 4 h, 6 h,
and 12/24 h). Increased ROS levels were revealed already
at 4–6 h after MCNA exposure (Huni132, Fig. 4a), while
bendamustine-treated cells showed unchanged ROS levels.
The earliest AnnexinV expression, however, was detect-
able after 12/24 h of drug treatment demonstrating that
the ROS increase precedes the induction of apoptosis.
According to these data we speculated that increasing
ROS levels are causally linked to the induction of early
apoptosis by the MCNA, which stands in contrast to the
p53-mediated activation of a ROS-independent DNA-
damage stress response and caspase-mediated apoptosis
by bendamustine.
To highlight the functional and specific role of ROS in
MCNA mediated killing of leukemic cells, we investigated
cell death (3 CLL cases) in the presence of the cell-
permeable ROS scavengers Tiron (chelator, scavenger of
superoxide ions and free electrons [32]), NAC (multi-
modal; antioxidant through GSH synthesis [33]), and
Deferasirox (oral iron-chelator in clinical use). These sub-
stances all mitigated the redox-induced apoptosis by the
MCNA as we observed a subtotal reduction of ROS and a
reduced degree of MCNA-triggered cell death in their
presence (Tiron, Fig. 4b). From that, we conclude that the
mode of anti-leukemic action of the MCNA is at least to a
high degree, but possibly not entirely, ROS dependent. In
agreement with our data on a rather selective cell death
induction by MCNA treatment in CLL tumor cells over
healthy-donor PBMC (Fig. 2a), we were also not able to
detect MCNA-induced ROS increases preceding the low
































1 1 8.4 8.2 1.3 1.1 4.1 4.4 1.3 1.5 4.1 3.9




































Fig. 3 (See legend on next page.)
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Fig. 3 The cell death induced by organometallic nucleosides in CLL is non-necroptotic and non-autophagic as well as independent of caspase-3
and p53. Representative immunoblots (12 % SDS gels, 20 μg protein load) of independent experiments on 8 CLL patient samples. Suspension
cultures were untreated or treated with 10 μM of each of the 4 metal-containing nucleoside analogues (MCNA) for 24 h following a 1 h pre-incubation
with the “analytic” inhibitor. (a) The MCNA trigger cleavage of PARP at various degrees without induction of cleaved effector caspase-3 (top panel) and
irrespective of the presence of the pan-caspase inhibitor Z-VAD (20 μM; top and bottom panel). In contrast, bendamustine (25 μM) mediates caspase-3
activation, which is Z-VAD responsive (top panel). (b) The inhibitor of necroptosis Necrostatin-1 does not noticeably affect the MCNA induced PARP
cleavage in CLL cells (staurosporine control experiments in online Supplements). (c) PARP cleavage in CLL cells promoted by the MCNA is
neither associated with pSer15-P53 activation nor with changes in levels of the autophagocytic marker protein LC3B-II (rapamycin control
experiments in online Supplements). The combination of the MCNA with the alkylator bendamustine enhances PARP cleavage alongside a
specific p53-phospho-activation, but without noticeable changes in levels of converted LC3B-II
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in healthy tissues.
We proposed that a major underlying factor for the
tumor-specific activity of the MCNA is the disturbed
redox equilibrium present in CLL cells [8, 10, 34]. In the
search for causative factors of elevated ROS in CLL [8],
we postulated that besides an increased mitochondrial
mass [34], oncogenic stress represents a leading force to-
wards this part of the aberrant redox signature of CLL.
Therefore, we decided to investigate this potential vul-
nerability aspect further by following the hypothesis that
one of the central oncogenes in CLL, TCL1, might repre-
sent a causal link. This is reasoned by TCL1’s activating
interaction with AKT [19, 35], a central growth-promoting
signaling node and an established inducer of oxygen free
radicals [36].
Higher levels of ROS and an associated increased
sensitivity towards metal-containing nucleosides are
linked to high TCL1 oncogene expression
Apart from their function in programmed cell death, intra-
cellular ROS are known to regulate a number of tumor-
associated signaling cascades particularly PI3K/AKT and
NFkB, the 2 major effector pathways of the lymphoid
oncogene TCL1 [35, 37, 38]. To explore the potentially
tight relation of tumor cell inherent ROS to TCL1, first
the number of TCL1+ cells within the CD5+/CD19+
CLL tumor cell population was correlated with the over-
all leukemic ROS levels by flow cytometry. In PB sam-
ples from 20 CLL, we observed a significant association
(rho 0.66, P < 0.002) of ROS levels with the percentage
of TCL1+ cell within the malignant clone (Fig. 5a left).
These results were confirmed in systems of modulated
TCL1. Eμ-TCL1-tg mice develop noticeable CD5+ B-cell
proliferations at 6–10 months resulting in overt CLL after
12–15 months [18]. Fittingly, the ROS levels in spleno-
cytes from 7-months old pre-leukemic, (Fig. 5a right-top)
and leukemic (not shown) TCL1-tg mice were signifi-
cantly higher than in splenocytes from age-matched
C3HxC57BL/6 wild-type controls. Similarly, introduction
of TCL1 in the CLL-like cell line JVM3 led to strongly ele-
vated ROS levels as compared to the parental cells (Fig. 5a
right-bottom). The findings from both experimentalsystems argue against the possibility that the elevated ROS
levels are predominantly a general cancer phenomenon
unrelated to TCL1 (TCL1 transfection of an already fully
transformed cell line; analysis of pre-leukemic mice) or to
be seen in the context of organismal/lymphocyte ageing
(age-matched animals). More likely, the results suggest
that the elevated TCL1 expression, characteristic for CLL
[19, 20], stands in a causal relation to a dysbalanced redox
state resulting in aberrantly high ROS levels.
We next analyzed whether TCL1 overexpression, linked
through the elevated ROS levels translates into altered
sensitivity towards our MCNA. Indeed, upon MCNA
treatment the amount of cleaved PARP was noticeably
higher in the TCL1-carrying JVM3 CLL-like B-cells than
in the parental line, which was confirmed by the num-
ber of AnnexinV expressing cells (not shown). In con-
trast, bendamustine sensitivity was slightly reduced by
stable TCL1 transfection (Fig. 5b, top), a phenomenon
we observe more strikingly for fludarabine in vitro and
in the clinical setting [19]. Similarly, TCL1-driven mur-
ine leukemias (Eμ-TCL1-tg splenocytes) showed a good
response to our novel agents (Fig. 5b bottom-left). Fur-
thermore, MCNA treatment elicited much stronger cyto-
toxic responses in TCL1-positive CLL as compared to
TCL1-negative cases (Fig. 5b bottom–right). Together,
these data demonstrate that high TCL1 oncogene ex-
pression directly associates with elevated cellular ROS
levels and by that mediates an increased vulnerability
towards MCNA.
Dependence on mitochondrial energetic flux renders
TCL1-positive cells more susceptible towards agents inter-
fering with mitochondrial homeostasis
The sensitivity to our MCNA that TCL1 oncogene over-
expression conferred via elevated ROS was intriguing as
it stands in contrast to a general TCL1-associated resist-
ance towards classical apoptosis inducing agents [19].
Therefore, we asked for the specific underlying mecha-
nisms of this vulnerability. Thus far, our results showed
that the apoptosis induced by MCNA does not rely on
active caspase-3 (Fig. 3a). We next investigated the re-
lease of mitochondrial proteins in response to apoptotic













































































































Fig. 4 (See legend on next page.)
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Fig. 4 The induction of CLL cell apoptosis by metal-containing nucleosides is ROS dependent. Flow cytometry with representative dot plots of 3
CLL samples. (a) Increasing ROS levels (detected by CM-H2DCFDA probe) following exposure to metal-containing nucleosides (MCNA; example
here Huni132) were noticeable at 4-6 h and were associated with the induction of early apoptosis (Annexin-V). Apoptosis induced by bendamustine
was not paralleled by increases of cellular ROS. * For bendamustine data are shown at 24 h instead of 12 h due to different cell-death kinetics,
however, at no time-point of bendamustine exposure a ROS increase was noted. (b) The increasing ROS levels (CM-H2DCFDA, solid grey
histograms represent Dmso controls) at 6 h that precede the induction of cell death by the MCNA (x: AnnexinV, y: 7AAD; max. at 24 h), but
not by bendamustine, are preferentially observed in CLL tumor cells as compared to healthy donor peripheral blood mononuclear cells (PBMC).
Pre-incubation (1 h) with several ROS scavengers, here Tiron (10 mM), partially abrogated the MCNA mediated ROS increase and reduced the
extent of overall apoptosis (AnnexinV+ fraction). MF: mean fold changes in mean fluorescence intensity. Lower-left quadrant %-ages indicate
AnnexinV/7AAD double-negative viable cells
Prinz et al. Molecular Cancer  (2015) 14:114 Page 10 of 18inducing factor (AIF), a known mediator of caspase-
independent apoptosis [31], Smac, the suppressor of the
inhibitors of apoptosis proteins (IAP) [39], and cyto-
chrome c, an electron transport protein released from
mitochondria during the early stages of apoptosis [40].
JVM3 CLL-like cells and their stable TCL1 transfectants
were treated with Huni132 or Huni218, and the protein
levels of AIF, Smac, and cytochrome c were analyzed in
cytosolic and mitochondrial fractions by immunoblots.
There were no obvious uniform changes in AIF, Smac,
or cytochrome-c levels at baseline (untreated cells).
However, most consistently, exposure to the MCNA re-
sulted in mitochondrial depletion of all three proteins in
the TCL1-transfected JVM3-cells (Fig. 6a). A simultaneous
cytosolic accumulation of these released molecules was
not captured at the parallel time points, which points to
different kinetics of their degradation and established nu-
clear trans-localization. Overall, these data implicate that
the presence of TCL1 promotes the apoptotic effects of
the MCNA at the mitochondrial level and involves media-
tors of caspase-independent pathways.
We next monitored bio-energetic rates of the two
major sources of cellular ATP generation, glycolysis and
mitochondrial respiration, in the context of substance
challenge and in relationship to the impact of TCL1.
Interestingly, basal mitochondrial respiration (OCR) was
not increased in TCL1-transfected cells (Fig. 6b). However,
basal aerobic glycolysis as indicated by lactate production
(ECAR), was significantly lower in the JVM3-TCL1 cells
(Fig. 6b). Furthermore, treatment with the complex-V in-
hibitor oligomycin reduced the OCR on average to 41 ±
7 % (of baseline level) in the TCL1-transfected JVM3 cells
vs 84 ± 4 % in the TCL1-negative JVM3 control (Fig. 6c).
Since the mitochondrial complex-V (F0F1-ATPase) cou-
ples the electron chain to ATP synthesis, this result of a
higher oligomycin-sensitive fraction indicates that TCL1
abundance is associated with a significantly higher fraction
of oxygen consumption being coupled to ATP-synthesis
(higher ATP turn-over). The maximal respiratory capacity
as determined by addition of the uncoupling agent FCCP
was not impacted in TCL1’s presence. The antimycin/rote-
none insensitive OCR fraction was lower in the TCL1condition indicating a lower contribution of the non-
mitochondrial component of OCR to overall respiration
under TCL1 impact.
In conjunction, these data implicate a TCL1-mediated
shift towards a higher relative contribution of the mito-
chondrial metabolism over glycolysis to overall ATP gen-
eration and over non-mitochondrial sources of oxygen
consumption to global respiration. It could partially pro-
vide an explanation for the increased ROS levels mediated
by TCL1 (Fig. 5). At the same time a stronger dependence
on mitochondrial energetic flux seems to render TCL1+
cells more susceptible towards agents interfering with
mitochondrial homeostasis such as the tested MCNA.The novel metal-containing nucleosides induce a rapid
mitochondrial depolarization in primary CLL cells
Under physiologic conditions, production of ROS is a
byproduct of normal ATP-dependent mitochondrial res-
piration [34]. Given the selective efficacy of our MCNA in
CLL acting through ROS induction and based on the
modulatory impact of the CLL oncogene TCL1 on mito-
chondrial metabolism, we hypothesized that the MCNA
induce cell death in primary CLL cells by significantly af-
fecting their mitochondrial function. We analyzed the res-
piration and membrane potential of mitochondria in CLL
samples after incubation with MCNA. We found that
mitochondrial respiration (OCR) is significantly reduced
upon MCNA exposure compared to bendamustine-,
fludarabine-treated or untreated CLL samples (Fig. 7a).
In addition, we assessed the mitochondrial membrane
potential (ΔΨM) as an established marker for mitochon-
drial fitness. The energy produced during mitochondrial
respiration is maintained as a high ΔΨM whereas de-
clining mitochondrial function or their destruction is
associated with a ΔΨM loss. As anticipated, application
of the MCNA, but neither bendamustine nor fludara-
bine, resulted in a rapid mitochondrial depolarization in
primary CLL cells suggesting that mechanistically our
MCNA promote ROS production in tumor cells by affect-
ing mitochondrial respiration and membrane polarization
(Fig. 7b, Additional file 1 Fig. S9).
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Fig. 5 Higher levels of ROS and an increased sensitivity towards metal-containing nucleosides are associated with high TCL1 oncogene expression.
(a) Left: overall cellular ROS levels (CM-H2DCFDA flow cytometry) positively correlate with the percentage of TCL1-expressing tumor cells in 20 freshly
isolated CLL (Spearman’s rho = 0.66, P = 0.0016). Adjustments by DoHH2 control cells in each individual measurement to address inter-experimental
variations are outlined in Materials and Methods. Right-top: basal cellular ROS levels in splenic B-cells from 7 months old TCL1-transgenic mice
(Eμ-TCL1 tg) are higher than in those from age-matched animals of identical C3HxC57BL/6 (C3B6) wild-type (WT) background (representative
histogram with mean fluorescence intensities (MFI) from measurements on 3 different mice). Right-bottom: Introduction of TCL1 into JCM3
CLL-like cells (stable transfectants JVM3-TCL1) leads to higher ROS levels (MFI; representative example of 3 independent measurements).
(b) Top: representative Western blot of 3 experiments of 24 h of metal-containing nucleoside treatment of JVM3 cells. A stronger PARP cleavage
is observed in the TCL1-expressing sub-line. The opposite is noted for the ROS-independent alkylator bendamustine. Numbers represent
densitometric ratios to Dmso controls of cleaved/non-cleaved PARP normalized to ß-Actin loading. Bottom-left: the same pattern of differential
induction of PARP cleavage across the substances is seen in leukemic Eμ-TCL1-tg mice (24 h, 1 representative of 3). Bottom-right: immunoblot
showing PARP activation in a selected pair of 6 CLL patient samples demonstrating a stronger PARP cleavage in TCL1-high cases than observed
for tumors expressing this oncogene at hardly detectable levels (Huni132 and Me-N69, both at 10 μM)
Prinz et al. Molecular Cancer  (2015) 14:114 Page 12 of 18Discussion
Cancer cells undergo various adaptations to cope with
(oncogenic) stresses and to secure a high-level energy
supply [13]. Targeting these metabolic consequences of
oncogene impact or loss of safeguarding tumor suppressor
function is increasingly recognized as a more fundamental
and specific approach than attempting to intercept in dis-
tinct oncogene addictions [36]. Oxidative stress, as exerted
by ROS, is strongly implicated in malignant transformation
and in responses to therapeutic agents. ROS act pro-
tumorigenic as signaling intermediates, e.g. in CLL down-
stream of BCR signals [14, 15], or by their DNA-mutagenic
effect. Although the dysbalanced redox homeostasis of
the neoplastic phenotype is associated with elevated ROS
levels, cancer cells also have a high anti-oxidant capacity
to ensure compatible ROS levels. For CLL cells, we
showed earlier that such a stress adaptation also involves
an enhanced mitochondrial biogenesis [34]. Overall, there
is a high level of oxidative stress as well as an elevated re-
sponse to it in cancer, hence, both sides of a delicate ROS
inducer/scavenger equilibrium represent promising Achil-
les’ heels for intervention [10, 36].
We previously exploited this principle by organochal-
cogens acting as sensor/effector catalysts inducing in-
tolerably high ROS levels especially in redox burdened
cancer cells, including those of CLL [7, 8]. Here, we ex-
panded on similar promising proof-of-principle data of
another rare set of substances, namely organometallic
nucleoside analogues [21–23]. We had identified before
the crucial roles of their cytosine nucleobase and metal
core (here now ferrocene, ruthenocene, and Fe(CO)3) in
cell death induction in lymphoblastic leukemia [21]. We
additionally provided the compounds with a protecting
5’-CH2O-TDS(thexyldimethylsilyl) substituent, because
this promised to add cytotoxic potential compared to a
sole 5’-OH group [41] in our lymphoblast systems. [21]
In the present study, the combination of these 3 ‘active’
groups in the 4 selected MCNA conferred a high in vitro
cytotoxic efficacy in CLL cells. This was specific over nor-
mal hematopoetic cells and could overcome the protectiveeffect by modeled milieu-derived signals (BMSC cocul-
tures). Most importantly, the MCNA were equally
efficient in CLL carrying low-risk aberrations vs those
with–11q or/and–17p, which are known to confer re-
sistance to conventional cytostatics, such as fludarabine
or bendamustine [24, 42]. In fact, our MCNA induced
impressive rates of cell death in the 9 clinically fludarabine-
refractory cases, of which at least 5 carried a–11q or/and–
17p high-risk lesion. Another poor-risk determinant,
unmutated (U) IGHV status, did not predict a poorer
MCNA response. In fact there was a tendency towards a
higher efficacy of certain MCNA in U-CLL, which might
find its correlate in their generally higher TCL1 levels [20]
in association with higher ROS levels (below).
These highly desirable features of targeting niche-
protected cells or those of genetically or clinically defined
resistance to agents inducing classical apoptosis chal-
lenged us to investigate the MCNA-mediated modes of
cell killing in more detail. We discovered here an induc-
tion of non-autophagic, non-necrotic apoptotic cell death
by MCNA exposure that did not entail p53 activation and
effector caspases. Moreover, this unconventional MCNA-
evoked apoptosis involved early cellular increases of ROS,
which proved indispensible for the induction of cell death.
These characteristics also distinguished our MCNA from
traditional cytostatics like bendamustine. It makes their
mechanistic action an attractive principle to overcome
more efficiently the resistance to classical apoptosis inher-
ent to CLL cells.
Generation of ROS, containment of their cytotoxic
potential via compartmental sequestration, and release of
caspase-dependent or -independent (e.g. AIF) execu-
tioners of apoptosis are mediated mainly by mitochondria.
Earlier, we described that non-mitochondrial production
of ROS by the membrane-bound NADPH-oxidase (NOX)
does not contribute to the elevated ROS levels in CLL
[34]. Fittingly, we found here that the increases in cellular
ROS by our MCNA preceding the induction of CLL
cell death were associated with severe disturbances of
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Fig. 6 Dependence on mitochondrial energetic flux renders TCL1-positive leukemic cells more susceptible towards agents interfering with
mitochondrial homeostasis. (a) Representative immunoblots on cytosolic and nuclear fractions from 3 experiments on CLL-like JVM3 cells and
their TCL1-positive sub-line after 24 h of metal-containing nucleoside treatment. Treatment with these substances reduces the levels of the
mitochondrial proteins AIF, smac, and cytochrome c in this subcellular fraction, specifically in the TCL1-overexpressing sub-line. (b, c) Mitochondrial
respiration (oxygen consumption rate; OCR) and extracellular acidification rate (ECAR; the result of anaerobic glycolysis) were measured (XFe96
flux analyzer) under basal conditions and in response to the indicated substances in JVM3 cells (control) and those transfected with TCL1.
(b) Left: baseline OCR is similar between JVM3 cells and their stable TCL1 transfectants, while a lower degree of ECAR in the presence of
overexpressed TCL1 is noted. (c) The effects on OCR are shown as percentages of baseline (set as 100 %) for each treatment (substances added
after 3rd, 6th, and 9th time-point). The stronger changes in OCR after oligomycin (ATP synthase inhibitor to differentiate the ATP-linked respiration from
the proton leak) in the TCL1-positive sub-line are indicative of higher degrees of respiration (OCR) linked to ATP synthesis. Maximal respiratory capacity
as determined by addition of the uncoupling agent FCCP was not different. Antimycin A/rotenone stop the reaction (respiration) and the remaining
level of OCR (non-mitochondrial respiration) is lower in the TCL1-carrying sub-line. All experiments of (b)-(c) were performed at least 6 times
with *** indicating P < 0.001 and bars for the standard error of the mean
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Fig. 7 The organometallic nucleosides induce a rapid mitochondrial depolarization in primary CLL cells. (a) Respiration (oxygen consumption
rate; OCR) is measured in primary CLL cells (n = 3) under basal conditions and in response to 10 μM fludarabine, 25 μM bendamustine, and
10 μM of the 3 most active metal containing nucleoside analogues (MCNA) in addition to a condition of 3 μM of the electron transport chain
inhibitors antimycin A/rotenone (specifically block mitochondrial respiration). OCR quickly and drastically drops after exposure to the MCNA,
but not after bendamustine or fludarabine. Percentages of OCR as compared to the baseline measurement (“before injection”, set as 100 %) are
shown. (b) The mitochondrial electrochemical membrane potential (ΔΨM) was semi-quantified in primary CLL-cells (n = 3) by flow cytometry
using the potentiometric dye JC-1. Histograms of a representative donor are shown in Additional file 1 Fig. S9. Changes in JC-1 mean fluorescence
index (MFI) were assessed upon treatment with 10 μM fludarabine, or 25 μM bendamustine, or 10 μM of each of the 3 most active MCNA. FCCP
(1.5 μM) an ionophore uncoupler was used as a positive control for reducing the mitochondrial membrane potential and accordingly JC-1 staining.
The MCNA, but neither fludarabine nor bendamustine, induce marked decreases in ΔΨM. Summarized results represent percentages of the MFI
of untreated control cells (set as 100 %). Significance levels: *P ≤ 0.05; ** P = 0.002
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markedly reduced upon MCNA treatment. Surprisingly,
bio-energetic characterizations of CLL cells are still rare.
However, this study corroborates previous notions by us
[7, 8, 34] and others [9, 10, 12, 43] that the amplifying
interconnection of elevated ROS generation and high-level
activity of adaptive mechanisms represent a metabolic
profile of CLL to be exploited more intensely in the future.
As we showed before that the mitochondrial electron
transport chain (mETC) in CLL is not uncoupled [34],
the actual causes of mitochondrial ROS accumulation in
CLL cells remain one of the most central questions. In
fact, we demonstrate for the first time data that implicatethe tumorigenic adapter molecule TCL1, an established
signaling modulator in CLL pathogenesis, in driving ele-
vated ROS levels. As underlying, we observed a reduction
of aerobic glycolysis and a higher fraction of oxygen con-
sumption coupled to ATP-synthesis, both to be mediated
by TCL1. This strongly suggests that TCL1 renders cells
more dependent on mitochondrial energetic flux through
which it acts as a powerful promoter of intrinsic ROS
overproduction in CLL.
TCL1 stands in multiple functional relationships to
other redox regulatory molecules of relevance in CLL.
For example, the TCL1-activated target kinase AKT
increases ROS by a fueled oxidative metabolism. Its
Prinz et al. Molecular Cancer  (2015) 14:114 Page 15 of 18activation can also mediate selective pressure towards a
more ROS tolerant phenotype as it can sensitize cells to
oxidative stress owing to the inactivation of Foxo tran-
scription factors, which in turn reduces expression of
anti-oxidant enzymes [44]. Another TCL1-cooperating
factor ATM [45], can be activated by ROS in the absence
of DNA double-strand breaks. Its safeguarding program
of ROS sensing and protective induction of autophagy
[46] likely fails in the context of genetic ATM deficiency
as found in up to 20 % of CLL, which are the cases with
the highest TCL1 levels [19, 20].
To build therapeutic principles around the non-kinase
chaperone TCL1 is a challenging task [47]. Therefore, it is
most intriguing that we discover here how TCL1 confers a
specific therapeutic susceptibility towards substances
interfering in mitochondrial homeostasis, particularly our
MCNA. We describe a TCL1-mediated enhanced depend-
ence on mitochondrial respiration in association with
elevated ROS. Furthermore, in the context of MCNA
exposure TCL1 promoted a marked mitochondrial deple-
tion of in part caspase-independent apoptotic factors, such
as AIF. Although CLL is a mostly TCL1-overexpressing
disease, dysregulated TCL1 is also found in other B-cell
lymphomas [48], T-cell prolymphocytic leukemia [49], and
some solid tumors [50]. Therefore, it will be of interest to
test if its disease-promoting properties can be turned into
an exploitable vulnerability in a broader spectrum of
entities by drugs that target redox systems or the mito-
chondrial metabolism. At the very least, we established
here that the high-level expression of otherwise pro-survival
TCL1 marks the problematic aggressive CLL subset with
resistance to conventional treatment [19, 20], but with ele-
vated sensitivity to redox-based strategies [43].
Conclusions
The aberrant phenotype of high-level oxidative stress
and altered mitochondrial metabolism in CLL can be ex-
plained by the impact of the lymphoid oncogene TCL1.
Redox-active substances such as organometallic (non-
conventional) nucleosides confer specific cytotoxicity to
such TCL1-overexpressing and ROS-burdened cells. With
respect to the chemistry-translated detailed modes of ac-
tion of our novel MCNA, we postulate also other mecha-
nisms besides a sole redox modulating (ROS quantity and
ROS composition) activity; the latter likely deriving from
the metal unit. These can involve engagements of certain
protein or receptor targets (predisposing steric bulk) or in
the case of Me-N69, release of the signaling intermediate
carbon monoxide (CO). Nevertheless, the clinical sig-
nificance of their mode of action via p53- and caspase-
independent induction of PARP-mediated non-classical
apoptosis lies in the potential of such (redox-based)
strategies to particularly overcome the notorious resist-
ance of clonal subpopulations or defined disease subsetsand to turn this into a marked interventional vulnerabil-
ity. These data justify the next level of studies on the




After obtaining written informed consent according to
guidelines of the Declaration of Helsinki and institutional
review board–approved protocols (#11–319) at Cologne
University, 40 individuals with the diagnosis of CLL based
on iwCLL criteria [51] provided peripheral blood (PB)
samples, which were taken ≥1 month after any anti-CLL
therapy. Their characteristics are indicated in Additional
file 1 Tables S1 and S2.
Sample purification and cell culture
Primary human CLL B-cells and murine splenocytes were
purified and cultured as described [52]. The minimum
purity (CD19+ or CD5 + CD19+ B-cells) of samples from
Eμ-TCL1 transgenic (tg) [18] mice and CLL patients was
90 %. Healthy-donor PB mononuclear cells (MC) were
isolated by density-gradient centrifugation. Human and
murine CLL cells were exposed to the substances (below).
For CLL-feeder cell cocultures, 1 × 10E6 cells of the human
bone marrow stroma cell (BMSC) line NK-tert reached ≈
60–70 % non-confluent density 24 h after plating, after
which freshly isolated primary CLL cells were added [26].
Drug exposure for 24 h started after most CLL cells had
firmly attached to the BMSC feeder layer (4 h) [26].
DoHH2 B-cell lymphoma and JVM3 CLL-like cells [53]
as well as their TCL1-overexpressing sub-lines (stably
transfected by a TCL1-overexpression construct [19,
54]) were cultured in RPMI1640 medium (Gibco, Life
Technologies; Carlsbad, California), supplemented with
penicillin (100 μg/ml), streptomycin (100 μg/ml), and
15 % fetal calf serum (FCS).
Compounds
All 4 organometallic nucleoside analogues used here were
checked for purity by 1H nuclear magnetic resonance
spectroscopy (NMR) after synthesis. The dry solids were
dissolved in dimethylsulfoxide (Dmso) as stock solutions,
which were kept at -20 °C with minimal exposure to light
and used at indicated concentrations and exposure times
(usually 10 μM for 24 h). Bendamustine (Mundipharma,
Limburg, Germany) was prepared as a water-diluted stock
solution and used at 25 μM. Rapamycin (20 μM) was from
Cell Signaling Technology (Cambridge, UK). Olaparib
(3 μM) and Staurosporine (1 μM) were from Selleckchem
(Houston, Texas, USA). Tiron (4, 5-Dihydroxy-1, 3-benze-
nedisulfonic acid), N-acetylcysteine (NAC), Necrostatin-1
(5-(1H–Indol–3–ylmethyl)–3–methyl–2–thioxo–4–Imi-
dazolidinone), and Dmso were from Sigma-Aldrich,
Prinz et al. Molecular Cancer  (2015) 14:114 Page 16 of 18Missouri, USA. Z-VAD-FMK (carbobenzoxy-valyl-ala-
nyl-aspartyl-(O–methyl)- fluoromethylketone) was both
from Promega (Fitchburg, Wisconsin, USA). Deferasirox
([4–[(3Z,5E)–3, 5–bis(6–oxo–1–cyclohexa–2, 4–dienyliden
e)–1,2,4–triazolidin–1–yl]benzoic acid) was from Novartis,
Basel, Switzerland. The ROS-scavengers Tiron, Deferasirox,
and NAC (all dissolved in water) were added to the cell
cultures at 10 mM, 1 h before exposure to the organo-
metallic nucleoside analogues. The necroptosis inhibitor
Necrostatin-1 (20 μM), the pan-caspase inhibitor Z-
VAD-FMK (20 μM), and the PARP inhibitor olaparib
(3 μM) were added to the cultures simultaneously to the
nucleoside analogues.
Analysis of apoptosis/cell viability
Dead cells or dying cells were quantified by flow cytome-
try (Gallios, Beckmann Coulter, Germany) via differential
AnnexinV-expression alongside incorporation of 7AAD
or Hoechst stain (Apoptosis Detection Kit I, BD Bioscience;
New Jersey, USA); e.g. apoptosis rate: %-AnnexinV/7AAD
or %-AnnexinV/Hoechst double-positive fraction. Differen-
tiation between B- and T-cells was achieved by staining for
CD19 Pacific Blue and CD3 APC (BioLegend; San Diego,
USA). As generally observed [25], incubation of CLL cells
in fresh medium for 24 h/48 h resulted in 5–30 % ‘spon-
taneous’ cell death. Therefore, in all experiments, un-
treated samples were collected at each time point and
the values for drug-induced cell death were normalized
to these controls. The colorimetric MTT (3–(4, 5–dimethyl-
thiazol–2–yl)–2, 5–diphenyltetra-zolium bromide) or MTS
(3–(4, 5–dimethylthiazol–2–yl)–5–(3–carboxymethoxyphe-
nyl)–2–(4–sulfophenyl) 2H-tetrazolium inner salt) assays
(both Promega; Fitchburg, Wisconsin, USA) assessed meta-
bolic activity and by that cell viability (in triplicates per sam-
ple), used according to the manufacturer’s instruction.
Immunoblotting
Protein lysates were separated by SDS-PAGE, transferred,
and probed with primary and secondary antibodies as de-
scribed [19]. For the analysis of cytochrome-c and AIF,
cytosolic and mitochondrial sub-cellular fractions were
separated using the mitochondria isolation Kit for Cul-
tured Cells (Thermo Scientific, Rockford, IL, USA). To en-
sure equivalent protein loading and transfer, all blots were
probed for β-actin. Unless otherwise indicated, all West-
ern blots shown in the figures are representative of three
independent experiments. Membrane probing included
the following primary antibodies: anti–human TCL1
(clone 1–21) [19]; anti-BCL2 (C-2), anti-AIF (D-20), and
anti-β-actin (C-11) from Santa Cruz Biotechnology, Texas,
USA; anti-phospho (p)-P53 (Ser15), anti-P53 (1C12),
anti-caspase-3, anti-cytochrome c, and anti-PARP from Cell
Signaling Technology, Massachusetts, USA.; anti-Smac/
Diablo from BD Transduction Laboratories, Germany; andanti-human LC3B from Novus Biologicals, Colorado, USA.
The HRP-conjugated species-specific secondary antibodies
were from Dianova, Germany. Band detection by chemilu-
minescence (Amersham Buchler, Germany) was followed
by densitometry by ImageJ (rsb.info.nih.gov/ij), including
normalization to β-actin expression.
Flow-cytometric detection of ROS
Cellular ROS levels were determined according to the
manufacturer’s instructions (ROS Detection Reagents
kit, Invitrogen Life Technologies, Carlsbad, USA) by
flow-cytometric recordings (Gallios, Beckmann Coulter,
Germany) of CM-H2DCFDA fluorescence. To ensure
consistency, we stained DoHH2-TCL1 cells (grown under
constant conditions) in each experiment in parallel and
corrected thereby for variable parameters/settings.
Extracellular flux assays
Bioenergetics of CLL-cells, B-cells, and JVM3-cells were
determined using the XF96e Extracellular Flux Analyzer
(Seahorse Bioscience, North Billerica, MA, USA). Cells
were seeded in specialized tissue culture plates at an op-
timized concentration of 240.000 cells/well and subse-
quently immobilized using CELL-TAK (BD Biosciences).
One hour prior to the measurement cells were incubated
at 37 °C in a CO2-free atmosphere. First, basal oxygen
consumption rate (OCR; indicator of mitochondrial respir-
ation) and extracellular acidification rate (ECAR; indicator
of lactic acid production or glycolysis) were recorded. Next,
OCR and ECAR changes upon application of oligomycin
(1 μM), the uncoupler FCCP (2.5 μM), a combination of
antimycin (3 μM) and rotenone (3 μM) (XF Cell Mito
Stress Test Kit, Seahorse Bioscience) as well as benda-
mustine (25 μM), and the metal-containing nucleosides
(10 μM) were evaluated. All experiments were per-
formed at least 6 times.
Mitochondrial membrane potential
Mitochondrial electrochemical membrane potential (ΔΨM)
was assessed using the potentiometric dye JC-1 (JC-1 Mito-
chondrial Assay Kit, Cayman Chemical). Cells were stained
with JC-1 according to the manufacturer’s instructions for
15 min at 37 °C followed by flow cytometry.
Statistics
Graphs were generated using Prizm (GraphPad, San Diego,
CA). Data were expressed as means ± 95 % confidence
interval (CI). Unpaired t-tests were used to compare the
mean values of different experimental groups. Histo-
grams from flow cytometry were obtained and analyzed
using the Cyflogic software (http://www.cyflogic.com).
Correlations between ROS levels and percentage of TCL1
positive CLL cells (CD5+/CD19+) were analyzed using
Spearman correlation analysis. P values of <0.05 were
Prinz et al. Molecular Cancer  (2015) 14:114 Page 17 of 18considered statistically significant. LD50s (induced cell
death in 50 % of treated cells) were calculated from the
dose response curves via non-linear regression analysis in
GraphPad Prism [54].
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